Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

James Hensarling

Rheumatology Flowood, MS Medical Doctor

NPI 1255334280 CMS profile 102582

4436 Mangum Dr., Ste A, Flowood, MS 39232

Open in the dashboard

General payments

$7,533

453 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$11,485 paid to institutions, not to them · program year 2019

Through program year 2023, James Hensarling of Flowood, MS is reported in the CMS Open Payments database as having received $7,533 across 453 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $11,485 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 67th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $37 2
2022 General $16 1
2021 General $2,567 151
2020 General $2,216 135
2019 General $2,697 164

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Hensarling
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to James Hensarling were reported at $0. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year James Hensarling Rheumatology median Middle half National median
2019 $2,697 $744 $153–$2,687 $163
2020 $2,216 $462 $98–$2,027 $114
2021 $2,567 $531 $101–$2,153 $132
2022 $16 $627 $125–$2,303 $149
2023 $37 $741 $145–$2,524 $160
2024 $0 $830 $166–$2,660 $164
2025 $0 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Amgen Inc. $2,007 113 payments
  2. AbbVie, Inc. $1,540 91 payments
  3. Pfizer Inc. $788 52 payments
  4. UCB, Inc. $692 53 payments
  5. Novartis Pharmaceuticals Corporation $523 31 payments
  6. Janssen Biotech, Inc. $448 26 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $240 12 payments
  8. Regeneron Healthcare Solutions, Inc. $226 15 payments
  9. Lilly USA, LLC $208 13 payments
  10. Genzyme Corporation $194 11 payments
  11. Other $667 36 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $7,514 452 payments
  2. Education $19 1 payment
Products named General payments · program years 2019–2023
  1. Prolia $832 49 payments
  2. COSENTYX $694 39 payments
  3. Enbrel Inflammation $661 37 payments
  4. Cimzia $639 50 payments
  5. XELJANZ $617 40 payments
  6. RINVOQ $582 36 payments
  7. SIMPONI ARIA $568 28 payments
  8. Enbrel Inflammation $551 30 payments
  9. Enbrel Inflammation $549 35 payments
  10. HUMIRA $547 33 payments
  11. Other $3,693 213 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

453 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record